Almirante continues to deepen its specialization in dermatology. This is reflected in 2025, as the company quadrupled its profits to €46.2 million thanks to its portfolio of biological treatments, compared to €10.1 million in 2024. Group sales exceeded €1 billion, specifically €1.108 billion, representing a 12.4% increase over the previous year. Total revenue was €1.114 billion, up 12.5%. Operating profit (EBITDA) reached €232.9 million, a 20.9% year-on-year increase, and the gross margin was 64.4%. The key driver of these results was dermatology sales in Europe, which increased by 25.6% to €608 million, the company reported in a statement on Monday.

Concern and unease. This is what the European pharmaceutical sector feels in the face of the advance of the US and China. This was expressed by Carlos Gallardo, president and CEO of Almirante and second vice-president of the European Federation of Pharmaceutical Industries and Associations (EFPIA). During a conference at Matins d'Esade, the representative of the family that controls the majority of Almirante's capital asserted that Europe was, "literally, the pharmacy of the world," and that this characteristic has been lost in the last three decades. "In 25 years, it has gone from contributing half of the innovative medicines to producing only one in five," he explained. Gallardo called on the European Union (EU) to modify its policy and consider the biopharmaceutical sector strategic for the future of the European economy, instead of as a cost center. He explained that investment in research and development (R&D) has fallen by 25% in the last 20 years in Europe, which is delaying the global launch of drugs. He also explained that the regulatory process is also too slow in Europe. As an example, he said that the European Medicines Agency (EMA) takes an average of 426 days to approve a product, while in the US, through the FDA, it takes 244 days. And, in Spain, another 600 days are added. Therefore, companies only have about six years to recoup their investment before the patent expires. During the audience question period, Gallardo called for a commitment to a hub He argued that having a "superpower" research center in Europe, like the one in Boston, USA, instead of one in every country, fragments everything and creates significant inefficiencies. The decline he believes is affecting the European sector also impacts clinical research. "European participation in clinical trials has halved, resulting in 60,000 fewer opportunities for patients." Furthermore, he noted that US and Chinese industrial policies are "redirecting manufacturing investment away from Europe." He also stated that Almirall is committed to artificial intelligence (AI) and explained the process that led the company to focus on medical dermatology. To this end, they consider many variables, from dermatologists' perceptions to the number of patients treated, sales growth, employee satisfaction, progress on the R&D roadmap, and reducing their carbon footprint, he concluded. It has been agreed that its objective is to launch products prescribed by dermatologists, outside the realm of cosmetics or aesthetics.

Pharmaceutical company Almirall increased its profits fivefold in the first three months of the year compared to the same period last year, according to a statement issued by the company to the Spanish National Securities Market Commission (CNMV). The company's profits rose from €7.2 million in the first three quarters of 2024 to €39.1 million in 2025.

Marc Murtra arrived at Telefónica with a vocation for change. First, with a promise of a new direction for the telecommunications company, with divestments and advocating for a more established European sector. Now he is materializing changes by remodeling his leadership, with a new right-hand man and new faces that come from Indra. Beyond Telefónica, Tous hires a new leader for its business in the United States and Almirall has a new financial director.

Catalan pharmaceutical group Almirall turns the page and returns to profit in its 2024 results. The company left losses behind and made a profit of 10.1 million euros compared to the negative 38.5 million in the previous year, it reported in a statement on Monday. The company has explained that its profits were "moderately affected by minor impairments."